» Articles » PMID: 37108118

Molecular and Pathological Analyses of IARS1-Deficient Mice: An IARS Disorder Model

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 28
PMID 37108118
Authors
Affiliations
Soon will be listed here.
Abstract

Most mitochondrial diseases are hereditary and highly heterogeneous. Cattle born with the V79L mutation in the isoleucyl-tRNA synthetase 1 (IARS1) protein exhibit weak calf syndrome. Recent human genomic studies about pediatric mitochondrial diseases also identified mutations in the IARS1 gene. Although severe prenatal-onset growth retardation and infantile hepatopathy have been reported in such patients, the relationship between IARS mutations and the symptoms is unknown. In this study, we generated hypomorphic IARS1 mutant mice to develop an animal model of IARS mutation-related disorders. We found that compared to wild-type mice, IARS mutant mice showed a significant increase in hepatic triglyceride and serum ornithine carbamoyltransferase levels, indicating that IARS1 mice suffer from mitochondrial hepatopathy. In addition, siRNA knockdown of the IARS1 gene decreased mitochondrial membrane potential and increased reactive oxygen species in the hepatocarcinoma-derived cell line HepG2. Furthermore, proteomic analysis revealed decreased levels of the mitochondrial function-associated protein NME4 (mitochondrial nucleoside diphosphate kinase). Concisely, our mutant mice model can be used to study IARS mutation-related disorders.

Citing Articles

Mechanisms and Future Research Perspectives on Mitochondrial Diseases Associated with Isoleucyl-tRNA Synthetase Gene Mutations.

Watanabe M, Sasaki N Genes (Basel). 2024; 15(7).

PMID: 39062673 PMC: 11276352. DOI: 10.3390/genes15070894.


A model organism pipeline provides insight into the clinical heterogeneity of TARS1 loss-of-function variants.

Meyer-Schuman R, Cale A, Pierluissi J, Jonatzke K, Park Y, Lenk G HGG Adv. 2024; 5(3):100324.

PMID: 38956874 PMC: 11284558. DOI: 10.1016/j.xhgg.2024.100324.


Predictive modeling provides insight into the clinical heterogeneity associated with loss-of-function mutations.

Meyer-Schuman R, Cale A, Pierluissi J, Jonatzke K, Park Y, Lenk G bioRxiv. 2024; .

PMID: 38585737 PMC: 10996635. DOI: 10.1101/2024.03.25.586600.

References
1.
Turvey A, Horvath G, Cavalcanti A . Aminoacyl-tRNA synthetases in human health and disease. Front Physiol. 2022; 13:1029218. PMC: 9623071. DOI: 10.3389/fphys.2022.1029218. View

2.
Lacombe M, Lamarche F, de Wever O, Padilla-Benavides T, Carlson A, Khan I . The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor. BMC Biol. 2021; 19(1):228. PMC: 8529772. DOI: 10.1186/s12915-021-01155-5. View

3.
Hanaford A, Cho Y, Nakai H . AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives. Orphanet J Rare Dis. 2022; 17(1):217. PMC: 9169410. DOI: 10.1186/s13023-022-02324-7. View

4.
Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View

5.
Ofir-Birin Y, Fang P, Bennett S, Zhang H, Wang J, Rachmin I . Structural switch of lysyl-tRNA synthetase between translation and transcription. Mol Cell. 2012; 49(1):30-42. PMC: 3766370. DOI: 10.1016/j.molcel.2012.10.010. View